117 related articles for article (PubMed ID: 21218648)
1. [Semenogelin and sperm motility inhibition: an update].
Yi C; He RS; Zhao H; Hao LN
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):1023-6. PubMed ID: 21218648
[TBL] [Abstract][Full Text] [Related]
2. [Advances in the study of Semenogelin I from human seminal vesicles].
Su SF; Wang ZJ
Zhonghua Nan Ke Xue; 2009 Apr; 15(4):364-6. PubMed ID: 19472915
[TBL] [Abstract][Full Text] [Related]
3. The GPI-anchored CD52 antigen of the sperm surface interacts with semenogelin and participates in clot formation and liquefaction of human semen.
Flori F; Ermini L; La Sala GB; Nicoli A; Capone A; Focarelli R; Rosati F; Giovampaola CD
Mol Reprod Dev; 2008 Feb; 75(2):326-35. PubMed ID: 17624925
[TBL] [Abstract][Full Text] [Related]
4. Physiological roles of semenogelin I and zinc in sperm motility and semen coagulation on ejaculation in humans.
Yoshida K; Kawano N; Yoshiike M; Yoshida M; Iwamoto T; Morisawa M
Mol Hum Reprod; 2008 Mar; 14(3):151-6. PubMed ID: 18203809
[TBL] [Abstract][Full Text] [Related]
5. Semenogelin, the main protein of the human semen coagulum, regulates sperm function.
de Lamirande E
Semin Thromb Hemost; 2007 Feb; 33(1):60-8. PubMed ID: 17253191
[TBL] [Abstract][Full Text] [Related]
6. Association of seminal plasma motility inhibitors/semenogelins with sperm in asthenozoospermia-infertile men.
Terai K; Yoshida K; Yoshiike M; Fujime M; Iwamoto T
Urol Int; 2010; 85(2):209-15. PubMed ID: 20720384
[TBL] [Abstract][Full Text] [Related]
7. [Activities of the fragments of semenogelin I: an update].
Hu C; Zhao H
Zhonghua Nan Ke Xue; 2013 Feb; 19(2):169-72. PubMed ID: 23441461
[TBL] [Abstract][Full Text] [Related]
8. Interaction analysis identifies semenogelin I fragments as new binding partners of PIP in human seminal plasma.
Tomar AK; Sooch BS; Raj I; Singh S; Yadav S
Int J Biol Macromol; 2013 Jan; 52():296-9. PubMed ID: 23085372
[TBL] [Abstract][Full Text] [Related]
9. Functional implications of membrane modification with semenogelins for inhibition of sperm motility in humans.
Yoshida K; Krasznai ZT; Krasznai Z; Yoshiike M; Kawano N; Yoshida M; Morisawa M; Tóth Z; Bazsáné ZK; Márián T; Iwamoto T
Cell Motil Cytoskeleton; 2009 Feb; 66(2):99-108. PubMed ID: 19089943
[TBL] [Abstract][Full Text] [Related]
10. Seminal factor VII and factor VIIa: supporting evidence for the presence of an active tissue factor-dependent coagulation pathway in human semen.
Lwaleed BA; Goyal A; Delves G; Gossai S; Greenfield RS; Cooper AJ
Int J Androl; 2007 Dec; 30(6):543-9. PubMed ID: 17459125
[TBL] [Abstract][Full Text] [Related]
11. Human Semenogelin 1 Promotes Sperm Survival in the Mouse Female Reproductive Tract.
Sakaguchi D; Miyado K; Iwamoto T; Okada H; Yoshida K; Kang W; Suzuki M; Yoshida M; Kawano N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486486
[TBL] [Abstract][Full Text] [Related]
12. [Inhibition activity of semenogelin and its peptides to human spermatozoa].
Wang ZJ; Zhang W; Wu HF; Xu YG
Zhonghua Nan Ke Xue; 2007 Jan; 13(1):42-5. PubMed ID: 17302034
[TBL] [Abstract][Full Text] [Related]
13. Semenogelin I: a coagulum forming, multifunctional seminal vesicle protein.
Robert M; Gagnon C
Cell Mol Life Sci; 1999 Jun; 55(6-7):944-60. PubMed ID: 10412373
[TBL] [Abstract][Full Text] [Related]
14. Blocking serine protease activity prevents semenogelin degradation leading to hyperviscous semen in humans.
Anamthathmakula P; Erickson JA; Winuthayanon W
Biol Reprod; 2022 May; 106(5):879-887. PubMed ID: 35098308
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma.
Zhao H; Lee WH; Shen JH; Li H; Zhang Y
Peptides; 2008 Apr; 29(4):505-11. PubMed ID: 18314226
[TBL] [Abstract][Full Text] [Related]
16. Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process.
de Lamirande E; Yoshida K; Yoshiike TM; Iwamoto T; Gagnon C
J Androl; 2001; 22(4):672-9. PubMed ID: 11451365
[TBL] [Abstract][Full Text] [Related]
17. Quantification of seminal plasma motility inhibitor/semenogelin in human seminal plasma.
Yoshida K; Yamasaki T; Yoshiike M; Takano S; Sato I; Iwamoto T
J Androl; 2003; 24(6):878-84. PubMed ID: 14581514
[TBL] [Abstract][Full Text] [Related]
18. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.
Robert M; Gibbs BF; Jacobson E; Gagnon C
Biochemistry; 1997 Apr; 36(13):3811-9. PubMed ID: 9092810
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of RSIY-11, a novel seminal peptide derived from semenogelin-1, which acts as a neutral endopeptidase inhibitor modulating sperm motility.
Fritz R; Mukherjee A; Zaghi S; Agalliu I; Jindal S; Tashima AK; Fricker LD; Davies KP
J Assist Reprod Genet; 2019 Sep; 36(9):1891-1900. PubMed ID: 31346917
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human sperm motility by contraceptive anti-eppin antibodies from infertile male monkeys: effect on cyclic adenosine monophosphate.
O'Rand MG; Widgren EE; Beyler S; Richardson RT
Biol Reprod; 2009 Feb; 80(2):279-85. PubMed ID: 18945989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
